In the past two decades, we have made great strides in all three areas (figure illustrating six articles featured on the cover of the journals). On the physiology front, our work establishes a novel model that underscores a probabilistic relationship between CFTR's cytosolic domains that bind the normal ligand ATP, and its membrane spanning domains where the chloride-conducting path is crafted. In the area of molecular pathophysiology, our studies provide detailed explanations for how different mutations cause distinct functional defects, which subsequently account for a wide spectrum of disease severity. These fundamental understanding of the CFTR protein also lays a solid foundation for our investigation in CFTR pharmacology. Our research not only unveils the mechanism of action for the first FDA-approved target therapy of CF, but also discovers new reagents that can synergistically work with the current medication (patent pending).
The above-described three-pronged approach has served Hwang's lab well for more than two decades. With the recent solution of the atomic structure of the CFTR protein, Hwang's lab is positioned at the forefront of taking advantage of the resulting physical and chemical insights to launching on new research directions aimed at structure-based drug design for the ultimate goal of overcoming CF. (Our research has been supported by the NIH, Cystic Fibrosis Foundation, American Heart Association, and MU Research Board. Industrial collaborations include Vertex Pharmaceuticals, AbbVie, Flatley Discovery Lab, and Pfizer.)
Research Funding George Davis, MD, PhD
The laboratory of Dr. George Davis has received a new NIH award starting Sept. 1, 2017 entitled, "Priming of vascular tube morphogenesis: Novel role for VEGF and downstream RhoA activation". This proposal was a multi-PI grant submission with Dr. Ondine Cleaver's laboratory from UT Southwestern Medical Center. The new grant is funded by the National Heart, Lung and Blood Institute and is a 4 year award for $1,590,875 (total costs). This proposal addresses a fundamental question that underlies how the vasculature forms during embryonic development and asks which growth factors are necessary for blood vessel formation and seeks to determine when they temporally act to control these events. The Davis lab has developed defined conditions whereby human endothelial cells can assemble into three-dimensional networks of tubes (which resemble capillary networks in vivo) in collagen or fibrin matrices in vitro. A combination of 5 growth factors, when added together under serum-free defined conditions, induces this capillary tube network assembly response and they are; stem cell factor, interleukin-3, stromal-derived factor-1, fibroblast growth factor-2 and insulin (Factors). The new grant addresses a role for vascular endothelial growth factor (VEGF), which for many years was thought to be the key regulator of blood vessel formation. However, this new work has demonstrated that VEGF fails to induce vessel assembly directly; rather, it acts instead as an upstream signal to activate endothelial cells so that they can respond better to the downstream-acting five Factor combination to assemble more efficiently into capillary tube networks. VEGF priming followed by Factor addition also stimulates endothelial cells to more actively recruit pericytes, leading to enhanced capillary tube maturation events, including vascular basement membrane matrix assembly. The proposal investigates the signaling pathways and specific molecular requirements that stimulate or suppress this upstream VEGF priming mechanism. This work has identified that a key component of VEGF priming involves the small GTPase, RhoA, which is a major regulator of the endothelial cell actin cytoskeletal apparatus. Both positive and negative regulators of RhoA activation are being investigated which affect the ability of VEGF to act as a primer for capillary formation and maturation in vitro and in vivo during vascular development. 
Recent Publications

Where are they now? Spencer Gaskin (2003-2007)
I was a graduate student in MPP for four years under the tutelage of Dr. Ron Korthuis who was a constant source of inspiration and knowledge. Along with contributions from the rest of the outstanding faculty and students I interacted with on a daily basis, I was able to obtain a Ph.D. for our work on ischemia/reperfusion injury and preconditioning mechanisms to prevent some of the most catastrophic sequelae of common medical conditions associated with cardiovascular disease. I went on to attend medical school at Mizzou, which was also an essential step in my training that has now taken me to an Interventional Cardiology Fellowship at the Mid America Heart Institute in Kansas City. After medical school I did an Internal Medicine residency training program at UT Southwestern in Dallas before returning to St. Louis for a fellowship in Cardiovascular Disease at Washington University. Now in my final year of training, I look back at my time in Columbia fondly and clearly recall the profound satisfaction of teaching in the Physiology course and lab as well as the ability to present and publish data at international meetings.
I am exceptionally grateful for the opportunities afforded by my time in Columbia and am able to use the knowledge I gained daily. Though it has been a while since I was doing animal experiments in the lab, the lessons I learned are universally applicable and the ability to question the how and why about everything have served me well in my clinical and research interests. More recently I have been looking at health care outcomes research and ways to improve the clinical care we provide as physicians and means to incorporate scientific advances into clinical practice. This website tells the background of NIH and how they award grants. Are you applying to the correct group? Are you not being funded because the group you chose to submit to does not support your type of research? This website explains how you should choose your source of funding.
Congratulations to our
Something to think about.
-Emma Montgomery
Upcoming Events
 University early move-in is August 13th. If there is something that you would like to add to your new page, any information from your old page, or add a link, let me know so I can update that for you.
-Liz Boyles
Here is the old website.
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